» Articles » PMID: 17957188

MLL Translocations, Histone Modifications and Leukaemia Stem-cell Development

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2007 Oct 25
PMID 17957188
Citations 616
Authors
Affiliations
Soon will be listed here.
Abstract

Translocations that involve the mixed lineage leukaemia (MLL) gene identify a unique group of acute leukaemias, and often predict a poor prognosis. The MLL gene encodes a DNA-binding protein that methylates histone H3 lysine 4 (H3K4), and positively regulates gene expression including multiple Hox genes. Leukaemogenic MLL translocations encode MLL fusion proteins that have lost H3K4 methyltransferase activity. A key feature of MLL fusion proteins is their ability to efficiently transform haematopoietic cells into leukaemia stem cells. The link between a chromatin modulator and leukaemia stem cells provides support for epigenetic landscapes as an important part of leukaemia and normal stem-cell development.

Citing Articles

Design of Potent Menin-KMT2A Interaction Inhibitors with Improved ADME Properties and Reduced hERG Affinity.

Chapsal B, Kimbrough J, Bester S, Bergstrom A, Backos D, Campos B ACS Med Chem Lett. 2025; 16(2):224-233.

PMID: 39967615 PMC: 11831402. DOI: 10.1021/acsmedchemlett.4c00311.


Bone marrow mesenchymal stromal cells support translation in refractory acute myeloid leukemia.

Lisi-Vega L, Pievani A, Garcia-Fernandez M, Forte D, Williams T, Serafini M Cell Rep. 2025; 44(1):115151.

PMID: 39932190 PMC: 7617453. DOI: 10.1016/j.celrep.2024.115151.


Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates.

Able M, Kasper M, Vick B, Schwach J, Gao X, Schmitt S Leukemia. 2025; 39(3):632-642.

PMID: 39870768 PMC: 11879846. DOI: 10.1038/s41375-024-02510-5.


Application of RNA-Based Next-Generation Sequencing Fusion Assay for Hematological Malignancies.

Fei F, Telatar M, Tomasian V, Chang L, Gust M, Yew H Int J Mol Sci. 2025; 26(2).

PMID: 39859151 PMC: 11765404. DOI: 10.3390/ijms26020435.


Progress Toward Epigenetic Targeted Therapies for Childhood Cancer.

Liapodimitri A, Tetens A, Craig-Schwartz J, Lunsford K, Skalitzky K, Koldobskiy M Cancers (Basel). 2025; 16(24.

PMID: 39766049 PMC: 11674401. DOI: 10.3390/cancers16244149.